Financial PerformanceAntigen revenues beat this quarter, increasing 5% year-over-year to $4.3 million.
Market ExpansionWith increased adoption in emerging markets and expansion into recombinant antigens, continued robust growth of this product line is expected.
Trade BenefitsMicrobix products are currently exempt from tariffs under the USMCA trade agreement, allowing sales into the U.S. without additional costs.